Warburg Pincus Near $7B PANTHERx Deal

Warburg Pincus Near $7B PANTHERx Deal

Warburg Pincus, a private‑equity firm that manages more than $100 billion in assets, is reported to be close to acquiring specialty pharmacy company PANTHERx Rare in a transaction valued at more than $7 billion, including debt. The deal is being pursued in partnership with the Abu Dhabi Investment Authority (ADIA), and while a finalisation is expected soon, the report cautions that the transaction is not yet complete and the timing could change.

PANTHERx Rare is headquartered in Pittsburgh and focuses on providing medicines and patient‑support services for rare and orphan diseases. The company is currently owned by an investor group that includes General Atlantic. Historically, Centene purchased PANTHERx in 2020 and subsequently sold the rare‑disease specialty pharmacy in 2022 to a consortium comprising General Atlantic, Nautic Partners, and The Vistria Group for an undisclosed amount; the sale was part of Centene’s strategy to concentrate on its core health‑insurance operations.

Warburg Pincus already holds several healthcare‑related investments, notably the START Center for Cancer Research and Simtra BioPharma Solutions, underscoring its continued interest in the sector.